Our research challenges norms and redefines what’s possible. We are leading the harm reduction movement by bridging the gap between innovation and public health science, by actively embracing public health data and by actively listening to the consumers to drive our strategic initiatives.
Our comprehensive patent portfolio encompasses modern breeding techniques and genetic engineering to produce proprietary tobacco lines with characteristics that give consumers a real choice.
In tobacco, our cutting-edge technologies, grounded in modern plant breeding and molecular intervention (genetic engineering and gene editing), respectively, enable targeted alterations in the level of nicotine and other nicotinic alkaloids.
Our proprietary approaches to these diverse ends are the subject of an extensive, worldwide patent portfolio complemented by a rigorous trade secrecy/know-how program. We also safeguard varietal innovations through plant patenting (US) and plant variety protection in the US and other signatory nations of the UPOV Convention.
We leverage our proprietary technologies not only through in-house development but also by way of strategic licensing. In addition, we have achieved and continue to realize substantial benefits from a number of partnering arrangements.